The development of new treatments for multiple myeloma would benefit from a systematic consideration of patient preferences. Read More ›
A subgroup analysis looked at isatuximab plus lenalidomide-bortezomib-dexamethasone as first-line treatment in transplant-eligible newly diagnosed multiple myeloma patients with high-risk cytogenetics. Read More ›
Longer-term efficacy results with isatuximab in combination with carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma are promising. Read More ›
Teclistamab in combination with daratumumab may yield improved clinical efficacy in patients with relapsed/refractory multiple myeloma who are heavily pretreated per updated results from the TRIMM-2 trial. Read More ›
Patients with relapsed/refractory multiple myeloma were treated with subcutaneous isatuximab through an on-body delivery system—a wearable bolus injector that is attached to the patient’s abdomen. Read More ›
In 2022, the COVID-19 pandemic continues to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums. Read More ›
Longer follow-up results of the phase 2 GRIFFIN trial demonstrated that the addition of daratumumab to RVd induction/consolidation in conjunction with ASCT, followed by 24 months of daratumumab-lenalidomide maintenance resulted in deep and durable responses, including stringent CR and MRD negativity rates, in patients with transplant-eligible NDMM. Read More ›
Results of the 18-month follow-up of the phase 1b/2 CARTITUDE-1 trial indicated that a single infusion of cilta-cel produced early, deep, and durable responses in heavily pretreated patients with RRMM, with manageable toxicity. Read More ›
These results indicate that quadruplet induction therapy with daratumumab plus carfilzomib, lenalidomide, and dexamethasone (D-KRd); ASCT; and MRD response–adapted D-KRd consolidation therapy yielded high MRD negativity rates in patients with NDMM. Read More ›
Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talquetamab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination. Read More ›